Phase 2 pMMR Clinical Trials
9 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–9 of 9 trials
Recruiting
Phase 2
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Colorectal CarcinomaOligometastasespMMR+2 more
First Affiliated Hospital of Zhejiang University51 enrolled1 locationNCT06850103
Recruiting
Phase 2
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Locally Advanced Rectal CarcinomapMMRMSS+1 more
Zhejiang University50 enrolled1 locationNCT05731726
Recruiting
Phase 2
Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）
pMMR/MSS Locally Advanced Rectal Cancer
Dechang Diao86 enrolled1 locationNCT07005570
Recruiting
Phase 1Phase 2
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Solid Tumor CancerAdult Refractory CancerEndometrial Carcinoma (EC)+2 more
GV20 Therapeutics350 enrolled3 locationsNCT07070518
Recruiting
Phase 2
The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
Advanced Colorectal Cancer in the Third-line Treatment and BeyondpMMR/MSS Advanced Colorectal Cancer
Shanghai Changzheng Hospital60 enrolled1 locationNCT06930118
Recruiting
Phase 1Phase 2
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Solid Tumor, AdultCutaneous MelanomaRefractory Cancer+3 more
GV20 Therapeutics365 enrolled13 locationsNCT05669430
Recruiting
Phase 2
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
Colorectal Cancer MetastaticMicrosatellite Stable Colorectal CarcinomaRefractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS36 enrolled2 locationsNCT06522919
Recruiting
Phase 2
XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
CapecitabineTislelizumabBevacizumab+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences52 enrolled1 locationNCT05970302
Recruiting
Phase 2
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
Unresectable Colon Cancer Peritoneal MetastasesPMMR/Ras/BRAF Wild-type
Second Affiliated Hospital, School of Medicine, Zhejiang University30 enrolled1 locationNCT05742425